October 20, 2014
The full Federal Circuit refused Monday to review a decision invalidating a Bristol-Myers Squibb Co. hepatitis B drug patent as obvious, even though the compound it was based on was later found to be toxic, but several judges argued strongly that the ruling makes it too hard to show a patent is not obvious.
August 26, 2014
Teva Pharmaceuticals USA Inc. on Tuesday urged the Federal Circuit to reject Bristol-Myers Squibb Co.'s bid for en banc rehearing of a decision invalidating the patent on its hepatitis B drug Baraclude as obvious, saying that Bristol-Myers' position "flies in the face" of settled law on obviousness.
July 15, 2014
Bristol-Myers Squibb Co. on Monday pressed the Federal Circuit for another chance to show its patent for hepatitis B drug Baraclude was valid, arguing that the court's decision affirming the patent invalid as obvious in a Teva Pharmaceuticals USA Inc. dispute conflicted with U.S. Supreme Court precedent.
June 12, 2014
The Federal Circuit on Wednesday affirmed a lower court's decision that a Bristol-Myers Squibb Co. patent covering the hepatitis B drug Baraclude is invalid as obvious because it made only minor changes to the prior art, in a win for generics maker Teva Pharmaceuticals USA Inc.
December 05, 2013
Bristol-Myers Squibb pushed a Federal Circuit panel on Thursday to revive its patent covering the hepatitis B drug Baraclude, alleging a lower court applied improper legal standards when it found in favor of generic-drug maker Teva Pharmaceutical Industries Ltd. and determined that Bristol-Myers' patent was obvious.
August 27, 2013
Bristol-Myers Squibb Co. on Monday urged the Federal Circuit to reverse a decision that invalidated its patent covering the hepatitis B drug Baraclude, arguing that the district court relied on faulty legal reasoning to determine that the drug was obvious in favor of generic-drug maker Teva Pharmaceutical Industries Ltd.